Title: NEWMEDS Innovative Medicine Initiative -- Accomplishments and Lessons from a Pre-Competitive Consortium.

There have been remarkable advances in genetics, molecular biology and imaging technologies and every year nearly 15,000 articles relating to schizophrenia and depression are published. Despite these notable advances, there have been few truly innovative new medications that have made it to the clinic. The EU Innovative Medicines Initiative attempts to address this gap through a series of consortia.

NEWMEDS was one of the first (initial application 2008) initiatives and it identified three major challenges: i) a lack of pathophysiology-accurate animal models guiding the drug discovery; ii) a lack of tools and tests in healthy volunteers that can provide early indication of efficacy; and iii) the reliance of clinical trials on symptom-based DSM-categories which inevitably lead to biologically heterogeneous groups of patients. To overcome these limitations, NEWMEDS brought together a consortium of expertise from seven leading universities, two SMEs, and ten EFPIA partners. The purpose of the project was not to develop new drugs -- but to develop new methods. Therefore, the focus was on new "pre-competitive" insights, methodologies and analytical methods the NEWMEDS.

Over its lifetime the NEWMEDS consortium: a) developed standardised animal models that focus on reliable cross-species endophenotypes (e.g. cognitive function) based on touch-screen technology which is analogous to what is used in clinical testing; b) develop fMRI and PET based paradigms which may serve as early or surrogate markers to provide guidance for drug development -- compatible with cross-species translation and developed new machine-learning methods of image analysis (PIPR); c) examined a set of genetic abnormalities (CNVs) closely linked with Schizophrenia (15q11, 15q13), validated their impact on human populations and developed homologous animal models that are now available to others; d) amassed the largest depression treatment cohort to look for pharmacogenetic biomarkers to stratify response to antidepressant treatments, but, did not find major stratifiers -- however this exercise did lead to a simple tool for assessing the clinical utility of any future biomarkers (*[www.depressiontools.org](www.depressiontools.org))*; and e) by bringing together the largest multi-industry clinical database in Schizophrenia and Depression -- identified how trials could be shorter and more efficient. But also identified how trials inadvertently enrol duplicate patients and built a potential solution for this problem (DupCheck - *[www.dupcheck.org](www.dupcheck.org)*).

While the NEWMEDS consortium itself has come to an end it provided several important lessons about the organisation of these consortia: especially the importance of long-term commitment, consistency of personnel involved, the necessity of focussed objectives and procedural flexibility. The IMI continues to be using this mechanism for a range of projects in Autism (EU-AIMS), Pain (EuroPain) and Cognition (PharmaCog).

Drug development in Psychiatry still remains a challenge. Since 2008 when this project was started, several major companies have disinvested from psychiatry highlighting the complexity of challenges in this area. Given this, such "pre competitive" consortia are even critical to make the advances to make the field attractive enough for commercial interests to then explore them.

The talk will provide more details about NEWMEDS, lessons learnt and some thoughts about the challenges and solutions for drug development in Psychiatry.
